Please help sharing this, thanks ! Needed: Dogs Diagnosed with Splenic Hemangiosarcoma Integrated Chinese Medicine Holdings Ltd. is sponsoring a study at the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania entitled: "Randomized Controlled Trial of the Effects of I’m-Yunity vs. Standard of Care Chemotherapy (Doxorubicin) in Dogs with Splenic Hemangiosarcoma" The study objective: To assess and compare the efficacy and side effects associated with the administration of I’m-Yunity, doxorubicin, or both in combination to positively impact the lifespan and quality of life in dogs diagnosed with splenic hemangiosarcoma. Recruitment for this study will start July 15th 2013. To be included in this study the following criteria must be met: 1. Your dog must have confirmation of the diagnosis of splenic hemangiosarcoma by biopsy following splenectomy. 2. At least 14 days must have passed since the day of surgery. 3. Your dog must be stable and not likely to require euthanasia within 4 weeks of starting the study as determined by the investigators. 4. You must be able to administer oral medication (multiple pills and capsules) to your dog. 5. You must be at least 18 years of age and be able to understand the study requirements. 6. You must be able to take your dog to the Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania located in Philadelphia for all study visits. 7. You must approve the administration of a chemotherapeutic, I’m -Yunity®, or both in combination as treatment for hemangiosarcoma. 8. Your dog cannot have received any treatment for cancer (chemotherapy or I’m- Yunity®) or currently be taking other herbal supplements. All study visits, diagnostics and study treatments are free of charge. If you are interested in having your dog participate in this study, please contact the Veterinary Clinical Investigations Center at 215-573-0302 or [email protected].
Posted on: Tue, 16 Jul 2013 03:44:38 +0000
Trending Topics
Recently Viewed Topics
© 2015